Given the potential role of SMG1 in tumor immunity and the fact that SMG1 expression varies in tumor samples, we stratified the patients based on changes in SMG1 expression (ΔSMG1) after anti-PD-1 antibody treatment (Pembrolizumab). This evidence concerns the gene SMG1 and neoplasm.